Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2016 | Take home message from EBMT for ALL

Giovanni Martinelli • 4 Apr 2016
EBMT 2016
Acute Lymphoblastic Leukemia Inotuzumab ozogamicin

Giovanni Martinelli, MD, from the University of Bologna, Bologna, Italy discusses the success of targeted drugs such inotuzumab ozogamicin in adult acute lymphoblastic leukemia (ALL) and suggests that physicians should rapidly adopt these new drugs for clinical use.
Recorded at the 42nd Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) in Valencia, Spain.

More from Giovanni Martinelli

1:42
CAR-T updates in AML and ALL
Giovanni Martinelli • 7 Dec 2019
1:20
Gilteritinib for FLT+ R/R AML
Giovanni Martinelli • 26 Oct 2019
1:01
Giovanni Martinelli: exciting CAR-T research
Giovanni Martinelli • 25 Oct 2019
1:36
Blinatumomab for R/R Ph+ AML
Giovanni Martinelli • 25 Oct 2019

Related Videos

4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
5:14
Is transplantation and chemotherapy still necessary for all patients with Ph+ ALL?
Robin Foà • 15 Apr 2024
2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals